Ablynx NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Ablynx NV Elects New Chairman Of Board
Ablynx NV announced that it is the intention of the Board to separate the roles of Chairman and CEO. The Board intends to elect Dr Fellner as Chairman to succeed Dr Moses who will remain Chief Executive Officer. The Company also announced that it is the intention of Dr Stephen Bunting and Mr Denis Lucquin to resign from the Ablynx Board.
Latest Developments for Ablynx NV
- Ablynx NV updates on ALX-071 and ALX-0962
- Ablynx NV to Present Pre-Clinical Proof-of-Concept Data on ALX-0761 at ACR
- Ablynx NV Updates on Phase II Part of Combined Phase I/II Study of Anti-IL-6R Nanobody, ALX-0061 Results
- Ablynx NV Updates on Results of Phase I/II Study with Anti-Il-6R Nanobody, ALX-0061, in Rheumatoid Arthritis Patients
Latest Key Developments in Biotechnology
- FDA designates Regado Biosciences Inc's REG1 in PCI as a fast track development program
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Amarantus BioScience Holdings Inc closes warrant solicitation and enters into $20 mln purchase agreement with Lincoln Park Capital Fund, LLC
- Neurovive Pharmaceutical to evaluate IPO of subsidiary in Taiwan
- Share this
- Digg this